Transitioning From Bortezomib to Ixazomib in Multiple Myeloma
Posted: Thursday, November 21, 2019
The long-term use of proteasome inhibitors may improve clinical outcomes for patients with newly diagnosed multiple myeloma; however, the results seen in clinical trials are often not achieved in real-world settings. Habte Yimer, MD, of Texas Oncology, and colleagues reported the preliminary results of the US MM-6 trial at the 2019 International Myeloma Workshop in Boston (Abstract OAB-014), which evaluated the efficacy of long-term proteasome inhibition that transitioned patients from bortezomib to ixazomib.
The study authors assigned 160 patients who were transplant-ineligible or transplant-delayed for over a year to receive ixazomib, lenalidomide, and dexamethasone until disease progression or toxicity. The investigators presented the preliminary results of the first 25 patients enrolled. Overall, most patients were older with higher stages of disease and had many comorbidities, including renal and urinary disorders (48%), peripheral neuropathy (28%), and cardiac disorders (24%).
At the cutoff date, actigraphy data for 24 patients were recorded, including the mean number of steps/day (3,236 steps/day) and sleep time (8.35 hours). Progression-free survival, overall survival, and response data were unavailable at the cutoff date. Although the patient population in US MM-6 were older and had advanced stages of disease, the results were similar to previously published results of long-term use of proteasome inhibitors, with high compliance rates.
The study will provide useful data on patient and disease characteristics and outcomes for patients with newly diagnosed multiple myeloma treated with ixazomib, lenalidomide, and dexamethasone and receiving long-term proteasome inhibitors, the authors concluded.
Disclosure: The study authors’ disclosure information can be found at imw2019boston.org.
